8290208090Open (affiliates only)A Phase III, randomized, multicenter, open-label, non-inferiority study
evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine
fixed dose combination in HIV-1 infected adults who are virologically suppressedIndustryAdultTreatmentIIIOtherKumar, PrincyGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Medicine Infectious Disease2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>